Research and Trials

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
Heart 01 Jan 2013

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

Clinical investigations have demonstrated a link between use of the sulfone cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, and increased risk for atherothrombotic events. This increased risk was not observed for a sulfonamide COX-2 inhibitor (celecoxib), indicating a potential non-enzymatic mechanism for rofexocib. To test this hypothesis, researchers compared the independent effects…
Bone 01 Jan 2013

An investigation into the short term effect of APOMINE in patients with Osteoporosis or Low Bone Mass

Osteoporosis affects millions of postmenopausal women in the USA. The current approved treatments are all drugs that prevent bone loss and possibly result in small gains in bone mass. Another possible treatment consists of drugs that increase bone formation. There are currently two drugs that stimulate bone formation, sodium fluoride…
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)
Heart 01 Jan 2013

Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)

To evaluate the effectiveness of aldosterone antagonist therapy in reducing all cause mortality in patients who have heart failure with preserved systolic function. Official Title Conditions – Cardiovascular Diseases- Heart Diseases- Heart Failure Study Type Interventional Study Design Treatment, Randomized, Double-Blind, Placebo Control Further Details BACKGROUND: Heart failure (HF)…
Prevention of cognitive decline in Alzheimer’s disease by ingested interferon alpha
Neurology 01 Jan 2013

Prevention of cognitive decline in Alzheimer’s disease by ingested interferon alpha

In this phase I-II parallel design, randomized, double-blind clinical trial we will determine if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in patients with dementia of Alzheimer’s type (AD) and whether ingested hrIFN-a treatment decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate…
Infections 01 Jan 2013

Linezolid in the Treatment of Complicated Skin and Soft Tissue due to Methicillin-Resistant Staphylococcus Aureus

This is a Phase IV randomized, multi-center, open label trial to compare the clinical safety and efficacy of linezolid to vancomycin in the treatment of complicated skin and soft tissue infections due to methicillin-resistant staphylococcus aureus in adult subjects hospitalized for at least one day. Official Title Linezolid in the…
Cancer 01 Jan 2013

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC). Official Title A Phase…
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Blood 01 Jan 2013

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes…
Cancer 01 Jan 2013

FASLODEX and AROMASIN in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient,…
Safety and Efficacy Study of CEP-10953 in the Treatment of Excessive Sleepiness Associated with Narcolepsy
Lungs 01 Jan 2013

Safety and Efficacy Study of CEP-10953 in the Treatment of Excessive Sleepiness Associated with Narcolepsy

The primary objective of this study is to determine whether treatment with CEP-10953 is more effective than placebo treatment for patients with excessive sleepiness associated with narcolepsy by measuring mean sleep latency from the Maintenance of Wakefulness (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500) and…